



COURT DETERMINES MAYNE PHARMA ENTITLED TO \$13.27M PAYMENT FOR LEGAL COSTS FROM COSETTE

22 May 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the Company) (ASX: MYX), is pleased to announce that Mayne Pharma has today been awarded \$13,269,328.04 in legal costs following its success in the proceedings last year against Cosette Pharmaceuticals, Inc (Cosette).

In June 2025, Mayne Pharma commenced proceedings against Cosette in the Supreme Court of New Wales (**Court**) in relation to Cosette's purported termination of the Scheme Implementation Deed signed by Mayne Pharma and Cosette in February 2025 (**Termination Proceedings**).

In October 2025, the Court delivered judgment in favour of Mayne Pharma dismissing all of Cosette's claims. The Court also made an adverse costs order against Cosette, requiring Cosette to pay Mayne Pharma's costs of the proceedings as agreed or assessed.

Today, the Court delivered judgment requiring Cosette to pay Mayne Pharma's legal costs of the Termination Proceedings in the amount of \$13,269,328.04, plus interest.

The Court is expected to make orders to give effect to the judgement shortly, including in relation to the amount of interest to be paid by Cosette, the timeframe for payment and with respect to Mayne Pharma's costs associated with its application for costs.

- ENDS -

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair.

Email Alerts

To register for an email alert service to receive Mayne Pharma announcements released to the Australian Securities Exchange (ASX) please visit <https://www.maynepharma.com/investor-relations/email-alerts/>

Follow us on [LinkedIn](#)

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia



ASX Announcement

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

